A Study to Evaluate the Effects of Ibrutinib on Cardiac Repolarization in Healthy Participants
Status:
Completed
Trial end date:
2015-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety and tolerability of ibrutinib, to compare
the pharmacokinetics of ibrutinib after single oral administration of 840 mg and 1680 mg and
to assess the effects of a single dose of ibrutinib on QT/QTc intervals and electrocardiogram
(ECG) in healthy adults.
Phase:
Phase 1
Details
Lead Sponsor:
Janssen Research & Development, LLC
Treatments:
Fluoroquinolones Moxifloxacin Norgestimate, ethinyl estradiol drug combination